Shots:

• The first patient has been dosed in the P-III registration clinical trial of ASC40 + bevacizumab in a ratio of (1:1) in 180 patients with rGBM. The company are expected to enroll ~180 patients at the end of Dec 2022
• The P-III trial will evaluate PFS, OS, and safety in patients with rGBM. In the P-II study, patients treated with ASC40 + bevacizumab showed ORR (65%) including a CR of 20% and a PR of 45%
• ASC40 is an oral, selective inhibitor of FASN & is designed to inhibit energy supply and disturb membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. The company has filed an IND application of ASC61 for the treatment of advanced solid tumors

Ref: PR Newswire | Image: Ascletis